Eli Lillyvs.Insulet
LLY vs PODD · both in Diabetes & metabolic disease, part of the Medicine, pharma & life science value chain: Treatment and monitoring of diabetes and metabolic disease, from insulin to glucose monitoring.
Eli Lilly is about 114× larger than Insulet by market cap; Insulet trades at the lower P/E (27.1 vs 43.2); year to date, Eli Lilly leads (+16.0% vs −48.8%).
Side by side
| LLY | PODD | |
|---|---|---|
| Market cap | $1.2T | $10.2B |
| Price | $1,233.66 | $143.05 |
| Today | −1.1% | −1.6% |
| Return YTD | +16.0% | −48.8% |
| Return 1Y | +75.2% | −56.0% |
| P/E | 43.2 | 27.1 |
| P/S | 14.5 | 3.3 |
| P/B | 34.0 | 6.7 |
Data as of 2026-08-26 · updates daily after U.S. close
The two companies
Eli LillyLLY
Mounjaro and Zepbound put Lilly at the centre of the GLP-1 market. Around them sit the diabetes and insulin business and franchises in oncology and neurology, with a pipeline that ranks among the strongest in the industry.
Full LLY profile →InsuletPODD
Maker of Omnipod, a tubeless insulin pump that handles dosing automatically.
Full PODD profile →More LLY & PODD comparisons
Other head-to-heads in the Diabetes & metabolic disease segment.